Explore the Agenda

Welcome to our pre-conference day! You can either attend three workshops (A or D, B or E, and C or F) scheduled at various times throughout the day, or choose to attend the Fundamentals of Radiopharmaceuticals Focus Day. If you have any questions about the layout or agenda, feel free to reach out to us at info@hansonwade.com.

Workshop Day

Workshop A

Using Patient-Centric Phase Zero Trials for Radiopharmaceutical Clinical Development

8:30 am Workshop A

Senior Director, Clinical Development, Alpha-9 Oncology
Vice President & Head of Biology & Translational, Rayzebio
Chief Medical Officer, AdvanCell

Serving as a bridge between preclinical and clinical development, phase zero studies can de-risk drug development by unlocking crucial pharmacokinetic and biodistribution data to optimize radiopharmaceutical drug candidates. Patient-centricity is at the core of phase zero studies and ethical considerations must be front and center in decision-making.

  • Join this discussion-based workshop to gain insights on:
  • Uncovering variations in compassionate use across countries like South Africa, Australia, Germany, and India, each with unique purposes and ethical considerations
  • Ensuring ethical practices in diagnostics trials and patient involvement, advocating against unnecessary patient risk
  • Guiding the design of Phase 1 trials by providing insights into optimal dosing, scheduling, and safety considerations
Workshop D

10:30 am Morning Break & Networking

Workshop B

Peptides, Mini Proteins & More: Delving into Challenges & Opportunities for Amino Acid Based Targeting Moieties

11:00 am Workshop B

Founder & CEO, VitsGen
Chief Executive Officer, Andarix Pharmaceuticals
Chief Development Officer, AI Proteins
Head Corporate Development, Radiopharma, Affibody

As the radiopharmaceuticals field diversifies, we see more companies using a range of targeting molecules. There are distinct opportunities and challenges for using smaller targeting formats based on circulation time, tumor retention, stability and kidney retention. It’s important to consider these properties when designing optimal radiopharmaceutical drugs.

Join this interactive deep dive to:

  • Explore challenges in integral membrane target identification and mining for peptides and mini proteins
  • Assess modifications to avoid kidney toxicities
  • Understand novel chelator innovations to explore how to alter pharmacokinetics and biodistribution
  • Addressing biological half-life and blending with payload
Workshop E

1:00 pm Lunch Break & Networking

Workshop C

Assessing Antibodies for Radiopharmaceuticals & Pre-targeting Strategies to Determine Success

2:00 pm Workshop C

Founder, Chairman & Chief Executive Offier, Transcenta
Chief Medical & Scientific Officer, Pentixapharm
Chief Executive Officer & Founder, OncoOne

Antibody conjugates have made blockbuster drugs in the ADC world and show promise to the radiopharmaceuticals field. While there are a large range of targets that can be addressed by antibodies, challenges in radiolabeling and biological halflife remain. Pre-targeting strategies may help unlock targeting specificity while matching biological half-life.

Join this interactive workshop to:

  • Discuss Zevalin and Bexxar, previous antibody-based drugs, their efficacy and wider contextual and commercial factors
  • Sharing novel prosthetic click-linker technologies
  • Outlining radiolabeling strategies
  • Exploring how to best match biological half-life with isotope half life
  • Sharing pre-targeting strategies
Workshop F

Fundamentals of Radiopharmaceuticals Focus Day

Harnessing Radiation for Precision Medicine: Introducing Radiopharmaceuticals Developmental Pathways

8:30 am Revealing the Lutathera & Pluvicto Stories from Bench to Bedside to Illustrate Prime Radiopharmaceutical Drug Development

Chief Medical Officer, Convergent Therapeutics, Inc
  • Exploring chemical structures, medicinal chemistry and delivery mechanisms
  • Understanding key steps for successful translation and early clinical design
  • Assembling the clinical workforce for the path to commercialization

9:00 am Outlining Radiopharmaceutical Diagnostics vs Therapeutics & the Path to Blended Theranostics

Global Clinical Head, Radiology & Nuclear Medicine, AstraZeneca

• Comparing diagnostic vs therapeutic landscapes and key nuances

• Understanding opportunities in theranostic development

9:30 am Panel Discussion: Commentary on Past & Future Developmental Pathways & Radiopharmaceutical Strategies

Chief Medical Officer, Convergent Therapeutics, Inc
Global Clinical Head, Radiology & Nuclear Medicine, AstraZeneca
  • Delving into the radiopharma landscape and technical development pathways
  • Sharing experiences

10:00 am Preclinical Techniques for Radiopharmaceuticals: The Gift of Dosimetry From Animal to Human

Director, PKS Modeling & Simulation, Novartis
  • Understanding biophysical characterization and pharmacokinetic understandings
  • Using in-vitro assays in radiopharma
  • Understanding important terminologies when using dosimetry

10:30 am Morning Break & Networking

Exploring Drug Design to Formulation Choices for Commercially Viable Radiopharmaceuticals

11:30 am Exploring Radiopharmaceutical CMC Processes & Supply Chain Considerations to Guide Development

Executive Vice President, Clarity Pharmaceuticals
  • Understanding radiochemistry and CMC processes
  • Exploring opportunities for downstream optimization
  • Navigating challenging supply chains

12:00 pm Designing a Radiopharmaceutical Clinical Trial: Key Considerations from the Start

Vice President, Medical Affairs, Radiopharm Theranostics
  • Outlining the network of clinical experts who are involved from nuclear medical physicians to medical oncologists
  • Key differences in a radiopharma trial
  • Radiation safety considerations

12:30 pm Hearing Patient Stories to Put the Field in Perspective

Chief Medical Officer, United Theranostics
  • Hearing how approved treatments have changed the lives of patients
  • Advocating patient-centricity in clinical design
  • Inspiring addressing more unmet medical need

1:00 pm Lunch Break & Networking

2:30 pm Question & Answer Session with Radiopharmaceutical Pioneers to Elevate your Industry Understandings

Vice President, Medical Affairs, Radiopharm Theranostics
Chief Medical Officer, United Theranostics
Executive Vice President, Clarity Pharmaceuticals
Chief Medical Officer, Convergent Therapeutics, Inc
Global Clinical Head, Radiology & Nuclear Medicine, AstraZeneca

Join our open session to ask your burning questions to the industry leaders ahead of the main conference to equip your team with expert knowledge ahead of the main conference.

Join this session to ask exactly what you want to know on topics like:

  • R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
  • CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
  • Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more